Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Post Q1 2024 Earnings of ($0.58) Per Share

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Vigil Neuroscience in a report released on Wednesday, March 27th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.58) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Vigil Neuroscience’s Q3 2024 earnings at ($0.58) EPS.

Separately, Morgan Stanley downgraded shares of Vigil Neuroscience from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $13.00 to $4.00 in a report on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Vigil Neuroscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.40.

Vigil Neuroscience Price Performance

VIGL stock opened at $3.41 on Thursday. The business has a 50-day moving average price of $3.06 and a 200 day moving average price of $4.32. The company has a market capitalization of $122.35 million, a P/E ratio of -1.60 and a beta of 1.80. Vigil Neuroscience has a 1-year low of $2.53 and a 1-year high of $11.11.

Hedge Funds Weigh In On Vigil Neuroscience

Several hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC increased its holdings in shares of Vigil Neuroscience by 0.9% during the second quarter. Citadel Advisors LLC now owns 2,180,324 shares of the company’s stock valued at $20,495,000 after acquiring an additional 18,528 shares in the last quarter. BlackRock Inc. boosted its position in Vigil Neuroscience by 704.7% in the second quarter. BlackRock Inc. now owns 821,452 shares of the company’s stock valued at $7,722,000 after buying an additional 719,366 shares during the last quarter. Vanguard Group Inc. boosted its position in Vigil Neuroscience by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 799,197 shares of the company’s stock valued at $2,701,000 after buying an additional 5,231 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in Vigil Neuroscience in the fourth quarter valued at approximately $1,809,000. Finally, Rock Springs Capital Management LP purchased a new stake in Vigil Neuroscience in the first quarter valued at approximately $3,318,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.